Organization | European Society of Cataract and Refractive Surgeons

European Society of Cataract and Refractive Surgeons Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2003

NCT00136344

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

ESCRS | ESCRS (European Society of Cataract and Refractive Surgeons) | European Society of Cataract and Refractive Surgeons

Active Ingredients

Drugs in Phase 3 Trials (7)

bevacizumab (avastin) (1 trial)

bromfenac (xibrom) (2 trials)

dexamethasone (1 trial)

ketorolac (acuvail) (1 trial)

phenylephrine (Prefrin) (1 trial)

triamcinolone (kenalog) (2 trials)

Drugs in Other Trials (2)

cefuroxime (zinacef) (1 trial)

levofloxacin (levaquin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Capsule Opacification (Phase 3)

Cataract (Phase 3)

Edema (Phase 3)

Macular Edema (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 9